|
| 信使RNA嵌合抗原受体细胞疗法研究进展 |
| Research progress of mRNA chimeric antigen receptor cell therapy |
| 投稿时间：2024-01-03 修订日期：2024-02-20 |
| DOI： |
|
 |
| 中文关键词: 嵌合抗原受体 信使RNA 癌症 细胞疗法 |
| 英文关键词:chimeric antigen receptors Messenger RNA Cancer Cell therapy |
| 基金项目:浙江省重点研发计划项目(No. 2021C03118) |
|
| 摘要点击次数: 51 |
| 全文下载次数: 0 |
| 中文摘要: |
| 近年来，病毒载体介导的嵌合抗原受体(Chimeric Antigen Receptor,CAR)细胞疗法已成为癌症治疗领域热点，并在血液系统恶性肿瘤患者中取得了显著的临床疗效，但其诱导的CAR永久表达可能导致严重不良反应。相较之下，信使RNA(Messenger RNA，mRNA)嵌合抗原受体疗法由于无插入性诱变和较小的靶外毒性风险，有望成为新一代更安全有效的治疗方法。该疗法通过将编码CAR的mRNA转染入效应免疫细胞中，以在体内产生免疫应答，已被应用于B细胞恶性肿瘤、淋巴瘤及急性髓细胞性白血病(Acute Myelogenous Leukemia,AML)等多种癌症的治疗。mRNA的提纯、修饰及转染技术的不断优化，使得CAR表达更为持久，杀伤效率更高，作用范围更广。本文综述了mRNA编码CAR递送优势及相关疗法研究进展。 |
| 英文摘要: |
| In recent years, viral vector-mediated Chimeric Antigen Receptor (CAR) cell therapy has emerged as a prominent topic in the field of cancer treatment and has demonstrated significant clinical efficacy in patients with hematological malignancies. However, the permanent expression of CAR induced by this therapy may give rise to severe adverse reactions. In contrast, Messenger RNA (mRNA) chimeric antigen receptor therapy is anticipated to become a new generation of safer and more effective treatments due to its lack of insertional mutagenesis and minimal risk of off-target toxicity. This therapeutic approach involves transfecting effector immune cells with CAR-encoded mRNA to elicit an immune response within the body. It has been employed for treating B-cell malignancies, lymphoma, Acute Myelogenous Leukemia (AML), and other cancers. The continuous optimization of mRNA purification, modification, and transfection technology enhances CAR expression durability while increasing killing efficiency and expanding the range of action.This article provides an overview of the advantages associated with MRNA-encoded CAR delivery and progress made in related therapies. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |